The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A study of ERG, PTEN, and ki-67 in a phase III trial assessing docetaxel and estramustine in high-risk localized prostate cancer (GETUG 12).
Shanna Rajpar
No relevant relationships to disclose
Philippe Vielh
No relevant relationships to disclose
Agnes Laplanche
No relevant relationships to disclose
Francois Lesaunier
No relevant relationships to disclose
Remy Delva
No relevant relationships to disclose
Gwenaelle Gravis
No relevant relationships to disclose
Frederic Rolland
No relevant relationships to disclose
Frank Priou
No relevant relationships to disclose
Jean-Marc Ferrero
No relevant relationships to disclose
Nadine Houede
No relevant relationships to disclose
Loic Mourey
No relevant relationships to disclose
Christine Theodore
No relevant relationships to disclose
Ivan Krakowski
No relevant relationships to disclose
Jean Francois Berdah
No relevant relationships to disclose
Marjorie Baciuchka
No relevant relationships to disclose
Muriel Habibian
No relevant relationships to disclose
Stephane Culine
No relevant relationships to disclose
Laura Faivre
No relevant relationships to disclose
Anne Chauchereau
No relevant relationships to disclose
Karim Fizazi
Consultant or Advisory Role - AstraZeneca; Keocyt; Sanofi